Keros Therapeutics (KROS) EBIT (2019 - 2025)
Keros Therapeutics posted quarterly EBIT of -$29.3 million for Q4 2025, up 45.04% year-on-year from -$20.2 million in Q4 2024, and down 90.26% on a QoQ basis from -$15.4 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of EBIT data on file, last reported at -$29.3 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT rose 45.04% year-over-year to -$29.3 million; the trailing twelve-month figure through Dec 2025 stood at $67.6 million (up 132.05% YoY), and the FY2025 full-year result was $67.6 million, up 132.05% from the prior year.
- EBIT for Q4 2025 stood at -$29.3 million, down from -$15.4 million in the prior quarter.
- Across five years, EBIT topped out at $152.0 million in Q1 2025 and bottomed at -$58.7 million in Q3 2024.
- The 5-year median for EBIT is -$31.3 million (2022), against an average of -$24.2 million.
- The widest annual swing landed in 2022, when EBIT tumbled 556.8%; it then surged 413.59% in 2025.
- A 5-year view of EBIT shows it stood at -$4.9 million in 2021, then sank by 556.8% to -$32.0 million in 2022, then sank by 45.35% to -$46.5 million in 2023, then decreased by 14.64% to -$53.3 million in 2024, then jumped by 45.04% to -$29.3 million in 2025.
- The last three EBIT figures came in at -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -29.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.27 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -39.82 Mn |
| Mar 31, 2025 | 152.04 Mn |
| Dec 31, 2024 | -53.25 Mn |
| Sep 30, 2024 | -58.66 Mn |
| Jun 30, 2024 | -50.44 Mn |
| Mar 31, 2024 | -48.48 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Sep 30, 2023 | -43.28 Mn |
| Jun 30, 2023 | -41.34 Mn |
| Mar 31, 2023 | -38.87 Mn |
| Dec 31, 2022 | -31.96 Mn |
| Sep 30, 2022 | -27.98 Mn |
| Jun 30, 2022 | -30.73 Mn |
| Mar 31, 2022 | -24.13 Mn |
| Dec 31, 2021 | -4.87 Mn |
| Sep 30, 2021 | -20.20 Mn |
| Jun 30, 2021 | -15.54 Mn |
| Mar 31, 2021 | -15.77 Mn |
| Dec 31, 2020 | -13.29 Mn |
| Sep 30, 2020 | -11.95 Mn |
| Jun 30, 2020 | -10.91 Mn |
| Mar 31, 2020 | -10.50 Mn |
| Dec 31, 2019 | -2.73 Mn |
| Sep 30, 2019 | -2.33 Mn |
| Jun 30, 2019 | -2.65 Mn |
| Mar 31, 2019 | -2.86 Mn |